StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) stock

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.96−0.05 (-1.25%)

Close on Nov 16, 2026Market cap $193.61MP/E –Yield –

Artiva Biotherapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Artiva Biotherapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$93.46M. For fiscal 2025 it was -$87.21M.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$87.21M–
FY2024Dec 31, 2024-$64.85M–
FY2023Dec 31, 2023-$28.41M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$26.20M–
Q1 FY2026Mar 31, 2026-$23.76M–
Q4 FY2025Dec 31, 2025-$21.27M–
Q3 FY2025Sep 30, 2025-$22.24M–
Q2 FY2025Jun 30, 2025-$22.17M–
Q1 FY2025Mar 31, 2025-$21.54M–
Q4 FY2024Dec 31, 2024-$17.65M–
Q3 FY2024Sep 30, 2024-$17.71M-255.8%
Q2 FY2024Jun 30, 2024-$15.59M–
Q1 FY2024Mar 31, 2024-$13.91M–
Q4 FY2023Dec 31, 2023-$11.38M–
Q3 FY2023Sep 30, 2023$11.37M–

More Artiva Biotherapeutics figures

See a number that looks wrong?